Last edited by Moogushura
Sunday, July 26, 2020 | History

2 edition of Selected abstracts on radiolabeled antibodies in cancer found in the catalog.

Selected abstracts on radiolabeled antibodies in cancer

Thomas P. Haynie

Selected abstracts on radiolabeled antibodies in cancer

by Thomas P. Haynie

  • 130 Want to read
  • 40 Currently reading

Published by U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Technical Information Service [distributor in [Bethesda, Md.], Springfield, Va .
Written in English

    Subjects:
  • Cancer -- Diagnosis -- Abstracts.,
  • Cancer -- Radiotheraphy -- Abstracts.

  • Edition Notes

    Other titlesRadiolabeled antibodies in cancer.
    StatementThomas P. Haynie, III, consulting reviewer.
    GenreAbstracts.
    SeriesOncology overview
    ContributionsInternational Cancer Research Data Bank.
    The Physical Object
    Paginationvii, 53 p. ;
    Number of Pages53
    ID Numbers
    Open LibraryOL17558113M

    Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, and easily available on a single library shelf or by a single personal subscription. Get this from a library! Cancer therapy with radiolabeled antibodies. [David M Goldenberg;] -- "Cancer Therapy with Radiolabeled Antibodies explores the most current experimental and clinical advances in the newly emerging field of cancer radioimmunotherapy (RAIT). Providing a.

    Abstract. This review focuses on the use of radiolabeled antibodies in the therapy of cancer, termed radioimmunotherapy (RAIT). Basic problems concerning the choice of antibody and radionuclide and the physiology of tumor and host are discussed. Request PDF | Cancer Imaging with Radiolabeled Monoclonal Antibodies | Noninvasive imaging technique using monoclonal antibodies (mAbs) is a rapidly evolving field, which has entered a new era of.

    Antibody targeting: Theoretical considerations --II. Model Systems Experimental model systems for antibody targeting and radioimmunodetection Preclinical models and methods for the study of radiolabeled monoclonal antibodies in cancer diagnosis and therapy Physiology of monoclonal antibody accretion by tumors   Oncodev Biol Med ; 1: 4. Mach JP, Chatal JF, Lumbroso JD, et al. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carci- noma. Cancer Res ; 5. Hnatowich DJ, Griffin TW, Kosciuczyk C, et al. Pharmacoki- netics of an indium-Ill labeled monoclonal antibody in cancer patients.


Share this book
You might also like
Punch card manual of instructions for judges of election

Punch card manual of instructions for judges of election

Progress againsttuberculosis.

Progress againsttuberculosis.

Beta decay

Beta decay

Economic consequences of high oil prices.

Economic consequences of high oil prices.

Indo-American library cooperation

Indo-American library cooperation

Brecht, women and politics =

Brecht, women and politics =

Technical assistance in Vietnam

Technical assistance in Vietnam

Critique of the report of the Royal Commission of Inquiry into contraception, sterilization and abortion in New Zealand

Critique of the report of the Royal Commission of Inquiry into contraception, sterilization and abortion in New Zealand

Sidney Janis presents an exhibition of 75 collages by Schwitters

Sidney Janis presents an exhibition of 75 collages by Schwitters

ESO Workshop on Stellar Evolution and Dynamics in the Outer Halo of the Galaxy

ESO Workshop on Stellar Evolution and Dynamics in the Outer Halo of the Galaxy

Canada [2010]

Canada [2010]

epoch in Canadian history -

epoch in Canadian history -

rescuers

rescuers

Voyage

Voyage

The Victorian Eye

The Victorian Eye

Selected abstracts on radiolabeled antibodies in cancer by Thomas P. Haynie Download PDF EPUB FB2

Get this from a library. Selected abstracts on radiolabeled antibodies in cancer. [Thomas P Haynie; International Cancer Research Data Bank.; Cancer Information Dissemination and Analysis Center for Diagnosis and Therapy.;].

The imaging of tumors using radiolabeled antibodies previously has required the implementation of computer-assisted subtraction techniques to reduce background radioactivity.

A decrease in radioactivity in the blood of hamsters bearing human colonic tumor xenografts has been achieved by administering a second antibody directed against a Cited by:   Radiolabeled Antibodies for Cancer Imaging and Therapy.

abstract, and list of authors), clicks on a figure, or views or downloads the full-text. may be selected. @article{osti_, title = {Cancer imaging with radiolabeled antibodies}, author = {Goldenberg, D M}, abstractNote = {This book presents a perspective of the use of antibodies to target diagnostic isotopes to tumors.

Antibodies with reasonable specificity can be developed against almost any substance. If selective targeting to cancer cells can be achieved, the. 38 Radiolabeled Antibodies for Cancer Imaging and Therapy In solid tumors, the future of radioimmunotherapy is often pre sented as a treatment of microscopic disease or even in the.

The article “Radiolabeled monoclonal antibodies” is the basis for this AORN Journal independent study. The behavioral objectives and examination for this program were prepared by Janet S. West, RN, BSN, CNOR, clinical editor, with consultation from Susan Bakewell, RN, MS(N), professional education specialist, Center for Perioperative Education.

Abstract. Radiolabeled antibodies were studied first for tumor detection by single-photon imaging, but FDG PET stopped these developments. In the meantime, radiolabeled antibodies were shown to be effective in the treatment of lymphoma.

Combined agents for synergy in ovarian cancer therapy. The anti-TAG antibody, CC49, was radiolabeled with Lu (a radiometal with β emissions similar to I) and given via intraperitoneal administration as a single agent or with human recombinant interferon-α (subcutaneous) with or without paclitaxel (Taxol) [9 •].

Eligible patients. Sharkey RM, Mabus J, Goldenberg DM. Factors influencing anti-antibody enhancement of tumor targeting with antibodies in hamsters with human colonic tumor xenografts. Cancer Res. Apr 15; 48 (8)– Sharkey RM, Primus FJ, Goldenberg DM. Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection.

Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of.

Abstract. The localization of antitumour monoclonal antibodies was studied in patients with colorectal cancer after intravenous injection. The monoclonal antibody T/36 was shown to localise in primary and secondary disease with a preferential uptake of.

Petersen BM Jr, Bass BL, Bates HR, et al: Use of the radiolabeled murine monoclonal antibody, In-CYT in the management of colon cancer. Am J Surg65 Although antibodies to CEA were among the first to be studied in a variety of cancers, Jeffrey Schlom, PhD, and David Colcher, PhD (National Cancer.

Two radiolabeled antibodies have been approved for the treatment of diffuse non-Hodgkin's lymphoma (Bexxar, Zevalin), but five other radiolabeled monoclonal antibodies, in.

Abstract. Paul Ehrlich’s concept of “magic bullet” for the cure of diseases has been revitalized by the development of the monoclonal antibody (Mab) technology allowing the production in unlimited amounts of antibodies of perfect homogeneity and.

Abstract. With the approval of 2 radiolabeled antibody products for the treatment of non-Hodgkin’s lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a new therapeutic modality, exemplifying the collaboration of multiple disciplines, including immunology, radiochemistry, radiation medicine, medical oncology, and nuclear medicine.

The findings in ovarian cancer patients with minimal disease are consistent with those in metastatic colonic cancer xenografts, where it has been observed that radiolabeled CEA antibodies can be curative of minimal metastatic disease (28,–), and that the highest rad doses delivered to tumor are inversely proportional to tumor size.

Abstract. Functional and constituent markers of neoplasms are being sought to elucidate differences between normal and malignant cells for diagnostic and therapeutic measures, and to provide leads to understanding mechanisms of cancer development, progression, and, ultimately, prevention.

and that radiolabeled antibodies can be used to. (1) Background: Monoclonal antibodies are used in the treatment of multiple conditions including cancer, autoimmune disorders, and infectious diseases. One of the initial steps in the selection of an antibody candidate for further pre-clinical development is determining its pharmacokinetics in small animal models.

The use of mass spectrometry and other techniques to determine the. Ideally, antibodies would rapidly accumulate at neoplastic sites and rapidly clear from the body; however, intact antibodies typically exhibit long circulation times in blood (which contributes to bone marrow toxicity) and a reduced diffusion into the tumoral mass, and may accumulate in critical organs, such as the liver ().The choice of the radionuclide largely depends on the size.

Purpose: To assess the current status of in-vivo use of monoclonal antibodies for treating cancer. Data Identification: Publications appearing between and were identified by computer searches using MEDLINE and CANCERLIT, by reviewing the table of contents of recently published journals, and by searching bibliographies of identified books and articles.

To discuss the scientific rationale for the use of monoclonal antibodies in cancer treatment and distinguish the unique characteristics of selected monoclonal antibodies.

Data Sources: Published scientific papers, abstracts, review articles, and book chapters. The antibody selected for ADC development is a major determinant of efficacy and toxicity in vivo.

In order to maximize the therapeutic index of an ADC, the antibody must have high specificity for the target antigen while exhibiting low uptake in normal tissues or cross-reactivity with other nonspecific antigens that can result in toxicity or faster rate of clearance.

.